3/4 of all hospitalised patients require a Peripheral Intravenous Catheter (PIVC), known as a 'drip' for treatments. PIVCs are necessary for treating but they can lead to life-altering bloodstream infections with a mortality rate of 25%. These infections are indiscriminate, costing the lives of the young and old alike.
TuCann is a cannula that reduces the risk of cannula associated bloodstream infection, focusing on both protecting the cannula during insertion and maintenance, thereby addressing all controllable sources of infection.
The value this brings to us is directed at each level of healthcare:
A cannula insertion that is more likely to be aseptic, reducing the risk of bloodstream infection. It also results in a faster cannulation experience, minimizing distress.
No more hunting around for the cannula trolley, no setting up a sterile field or priming a needleless connector.
A faster patient turnover, and savings from the prevention of PIVC-associated bloodstream infection (PIVC-BSI). Each episode of PIVC-BSI costs hospitals $45,000 USD.
It is estimated that if bloodstream infection rates were reduced by just 1, then 150,158 bed days would be released for alternative uses, allowing an estimated 38,500 additional admissions annually, reducing hospital waiting times and expenditure. Our design is aiming to reduce 25% of all blood stream infections.
Sign up to hear from us.
Mechanical Design Engineer
Please send us a message or call us to learn more about what we're doing!